Natera (NASDAQ:NTRA) Director Rowan Chapman Sells 2,964 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) Director Rowan Chapman sold 2,964 shares of the company’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $216.78, for a total transaction of $642,535.92. Following the transaction, the director owned 3,124 shares of the company’s stock, valued at $677,220.72. This trade represents a 48.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Natera Stock Performance

Shares of NASDAQ:NTRA opened at $226.44 on Thursday. The company has a fifty day moving average of $207.35 and a 200-day moving average of $215.50. The company has a market capitalization of $32.43 billion, a PE ratio of -138.92 and a beta of 1.56. Natera, Inc. has a 52-week low of $131.81 and a 52-week high of $256.36.

Institutional Trading of Natera

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. NewEdge Advisors LLC increased its holdings in Natera by 3.4% in the first quarter. NewEdge Advisors LLC now owns 5,452 shares of the medical research company’s stock valued at $1,090,000 after purchasing an additional 179 shares during the period. Groupama Asset Managment grew its holdings in Natera by 3.0% during the 1st quarter. Groupama Asset Managment now owns 95,061 shares of the medical research company’s stock worth $19,011,000 after acquiring an additional 2,805 shares during the period. Oddo BHF Asset Management Sas acquired a new stake in Natera during the 1st quarter worth about $6,410,000. Bull Harbor Capital LLC acquired a new stake in Natera during the 1st quarter worth about $1,543,000. Finally, Encore Global Management LP acquired a new stake in Natera during the 1st quarter worth about $1,200,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on NTRA shares. Royal Bank Of Canada started coverage on shares of Natera in a report on Thursday, June 11th. They set an “outperform” rating and a $275.00 price target for the company. The Goldman Sachs Group started coverage on Natera in a report on Friday, June 5th. They issued a “neutral” rating and a $245.00 price objective for the company. Wells Fargo & Company increased their price objective on Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. William Blair started coverage on Natera in a report on Tuesday, April 14th. They issued an “outperform” rating for the company. Finally, Morgan Stanley decreased their price objective on Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a report on Tuesday, March 3rd. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Natera has an average rating of “Moderate Buy” and a consensus target price of $256.53.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.